Provided are methods of immunizing a viewport of a medical device against fogging before or during a medical procedure, and related apparatuses and devices. The methods comprise applying plasma to the viewport prior to use, thereby rendering a surface of the viewport highly hydrophilic. The methods eliminate or at least significantly reduce blur due to fogging.

A method for elevating a TRAIL-R1 expression in cancer cells to induce apoptosis. The method comprises the steps of receiving electrical energy having a specific voltage, frequency and power from an electrosurgical generator, up-converting the voltage and down-converting the frequency with a high voltage transformer having a primary coil and a secondary coil, the secondary coil having a larger number of turns than the primary coil, applying said converted electrical energy to an electrode in an electrosurgical hand piece, flowing an inert gas through said electrosurgical hand piece to produce a cold plasma at a distal end of said electrosurgical hand piece; and applying said cold plasma to cancer cells for 1 to 3 minutes. The inert gas may comprise, for example, helium or argon. In a preferred embodiment the cold plasma is applied to cancer cells for about 2 minutes.

A system that does conversion from regular hot plasma produced by ESU to cold plasma which is thermally harmless for the tissue. The system is comprised of Conversion Unit and Cold Plasma Probe. Output signal for ESU connects to CU along with Helium flow. The CU converts signal from ESU and send it to the output connector along with helium flow. Cold Plasma Probe is connected directly to the CU output. At the end of the CPP probe cold plasma is produced.

A method and device to apply a cold plasma to a substance at a treatment surface of a patient to cause electroporation of the substance into cells of the patient. The substance can be previously applied to the treatment surface. Alternatively, the substance can be placed in a foam-like material within a tip that passes the cold plasma from the cold plasma device to the treatment area. The tip can be a cannula device with an aperture at the distal end. The cannula device can also have apertures along a portion of the length of the cannula device.

An elongate electrode is configured to flex and generate plasma to incise tissue. An electrical energy source operatively coupled to the electrode is configured to provide electrical energy to the electrode to generate the plasma. A tensioning element is operatively coupled to the elongate electrode. The tensioning element can be configured to provide tension to the elongate electrode to allow the elongate electrode to flex in response to the elongate electrode engaging the tissue and generating the plasma. The tensioning element operatively coupled to the flexible elongate electrode may allow for the use of a small diameter electrode, such as a 5 m to 20 m diameter electrode, which can allow narrow incisions to be formed with decreased tissue damage. In some embodiments, the tensioning of the electrode allows the electrode to more accurately incise tissue by decreasing variations in the position of the electrode along the incision path.

The present invention relates to a method for preparing a plasma for preventing or treating a cancer. Also, the present invention relates to a liquid type plasma for preventing or treating a cancer prepared by treating the plasma and a pharmaceutical composition for preventing or treating a cancer comprising the same. The plasma and the liquid type plasma according to the present invention can effectively induce cancer cell death without a surgical operation or in a treatment process after a surgical operation, thereby being useful as a novel therapeutic agent and method for a cancer.

A method for preparing cold atmospheric plasma stimulated cell culture media with a cold atmospheric plasma system having a delivery port out of which an inert gas flows. The inert gas may be helium. The method comprises the steps of placing a cell culture media in a first well, the first well having a bottom and having a diameter greater than 20 mm; wherein the cell culture media placed in the first well has a volume of 4 ml or less, treating the cell culture media in the first well with cold atmospheric plasma, wherein the treating is performed with a gap between the delivery port and the bottom of the first well is between 2.5 cm and 3.5 cm, and transferring a portion of the treated media to cultured cancer cells in a second well. The cold atmospheric plasma may be applied for 0.5 minutes to 2 minutes.

A device for treating living cells by plasmaporation contains, in addition to devices for generating plasma and generating a field, devices for mixing and transporting active substances, predominantly in the form of nano and microparticles, for affecting the metabolism of the cells.

A nozzle for attachment to a cold plasma device configured to maintain delivery of a stable cold plasma. The nozzle can have many different shaped apertures to support different applications requiring different shaped cold plasma plumes. Use of a disc of foam material within a nozzle can expand the size of aperture of a nozzle while maintaining delivery of a stable cold plasma. The nozzle can be an elongated cannula tube for internal delivery of a cold plasma treatment. The cannula tube can provide an aperture at its distal end or one or more apertures along its length. A shroud can partially enclose the distal aperture of the nozzle. A sterile sleeve can be used in conjunction with a nozzle to provide a sterile means of attachment and operation of the nozzle with a cold plasma device. In addition, various shaped apertures may be deployed to provide selective targeting of the cold plasma to a treatment area, while shielding other biological structures from cold plasma exposure. Such apertures also provide an opportunity for manual manipulation of tissues in the treatment area prior to or during cold plasma treatment.

A wearable cold plasma system includes a wearable cold plasma applicator configured to couple to a surface of a user wearing the wearable cold plasma applicator and configured to generate a cold plasma. The wearable cold plasma applicator is in the form of a cuff having one or more electrodes configured to generate the cold plasma within a cavity of the cuff. The wearable cold plasma system also includes a controller coupled to the wearable cold plasma applicator, and the controller is configured to produce an electrical signal that forms the cold plasma with the wearable cold plasma applicator.